Structure-activity relationship studies of anti-bunyaviral cap-dependent endonuclease inhibitors
Bioorganic & Medicinal Chemistry Letters · 2023-03 · 83 · 129175
DOI: 10.1016/j.bmcl.2023.129175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023-03. Verfasst von Yoshiyuki Taoda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shionogi Pharmaceutical Research Center, Shionogi & Company, Limited, 1-1, Futabacho, 3-chome, Toyonaka 561-0825, Japan. Electronic address: yoshiyuk…. Hauptthemen laut MEDLINE: Orthomyxoviridae, Influenza, Human. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Bunyaviruses, including the Lassa virus (LASV), are known to cause hemorrhagic fever and have a high fatality rate among hospitalized patients, as there are few effective treatments. We focused on the fact that bunyaviruses use cap-dependent endonuclease (CEN) for viral replication, which is similar to influenza viruses. This led us to screen carbamoyl pyridone bicycle (CAB) compounds, which compose a series of baloxavir acid (BXA) derivatives, against lymphocytic choriomeningitis virus (LCMV) and Junin virus (JUNV) among the bunyaviruses. This led to the discovery of 1c, which has potent anti-bunyaviral activities. In SAR studies, we found that a large lipophilic side chain is preferred for the 1-position of the CAB scaffold, similar to the influenza CEN inhibitor, and that a small alkyl group for the 3-position shows high activity. Moreover, the 7‑carboxyl group of the scaffold is essential for anti-bunyaviral activities, and the antiviral activity is reduced by conversion to various carboxylic acid bioisosteres. The SAR results are discussed using a binding model of 9d in the active center of the known LCMV CEN crystal structure. These compounds show promise as broad-spectrum anti-bunyavirus therapeutics, given their relatively favorable metabolic stability and PK profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shionogi Pharmaceutical Research Center, Shionogi & Company, Limited, 1-1, Futabacho, 3-chome, Toyonaka 561-0825, Japan. Electronic address: yoshiyuki.taoda@shionogi.co.jp.
- Shionogi Pharmaceutical Research Center, Shionogi & Company, Limited, 1-1, Futabacho, 3-chome, Toyonaka 561-0825, Japan; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido Univers…
- Shionogi Pharmaceutical Research Center, Shionogi & Company, Limited, 1-1, Futabacho, 3-chome, Toyonaka 561-0825, Japan.
- Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Hokkaido 001-0020, Japan.
- Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Hokkaido 001-0020, Japan; International Collaboration Unit, International Institute for Zoonosis Control, H…
Zitieren
APA
Taoda, Y., Sato, A., Toba, S., Unoh, Y., Kawai, M., Sasaki, M., Orba, Y., & Sawa, H. (2023). Structure-activity relationship studies of anti-bunyaviral cap-dependent endonuclease inhibitors. Bioorganic & Medicinal Chemistry Letters, 83, 129175. https://doi.org/10.1016/j.bmcl.2023.129175
Vancouver
Taoda Y, Sato A, Toba S, Unoh Y, Kawai M, Sasaki M, et al. Structure-activity relationship studies of anti-bunyaviral cap-dependent endonuclease inhibitors. Bioorganic & Medicinal Chemistry Letters. 2023;83:129175. doi:10.1016/j.bmcl.2023.129175
BibTeX
@article{Taoda2023,
author = {Taoda, Yoshiyuki and Sato, Akihiko and Toba, Shinsuke and Unoh, Yuto and Kawai, Makoto and Sasaki, Michihito and Orba, Yasuko and Sawa, Hirofumi},
title = {Structure-activity relationship studies of anti-bunyaviral cap-dependent endonuclease inhibitors},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2023},
volume = {83},
pages = {129175},
doi = {10.1016/j.bmcl.2023.129175}
}
EUVIMED